Alternative use of multiple exons 1 of aromatase gene in cancerous and normal breast tissues from women over the age of 80 years

[1]  Dayong Wu,et al.  Age-associated inflammatory changes: role of nutritional intervention. , 2007, Nutrition reviews.

[2]  D. Bernard,et al.  Normal or stress-induced fibroblast senescence involves COX-2 activity. , 2007, Experimental cell research.

[3]  N. Suzuki,et al.  Aging stimulates cyclooxygenase-2 expression and prostaglandin E2 production in human periodontal ligament cells after the application of compressive force. , 2007, Journal of periodontal research.

[4]  R. Karas,et al.  Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. , 2006, Journal of the American College of Cardiology.

[5]  Roberto Pacifici,et al.  Estrogen deficiency and bone loss: an inflammatory tale. , 2006, The Journal of clinical investigation.

[6]  N. Harada,et al.  Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years. , 2006, The Journal of clinical endocrinology and metabolism.

[7]  Shiuan Chen,et al.  Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  Y. Soini,et al.  17β-Hydroxysteroid Dehydrogenase Type 1 Is an Independent Prognostic Marker in Breast Cancer , 2004, Cancer Research.

[9]  A. Børresen-Dale,et al.  Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer , 2003, Breast Cancer Research.

[10]  R. Gelber,et al.  Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Mitch Dowsett,et al.  Aromatase inhibitors in breast cancer. , 2003, The New England journal of medicine.

[12]  S. Akinaga,et al.  Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. , 2003, Cancer research.

[13]  N. Harada,et al.  Breast carcinoma in women over the age of 85: distinct histological pattern and androgen, oestrogen, and progesterone receptor status , 2003, Histopathology.

[14]  Peter Devilee,et al.  Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2003 .

[15]  M. Dowsett,et al.  Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  L. Panasci.  Aromatase inhibitors: treatment of advanced breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Mayeux,et al.  Endogenous estrogen levels and Alzheimer’s disease among postmenopausal women , 2000, Neurology.

[18]  H. Sasano,et al.  17 β -Hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters , 2000, British Journal of Cancer.

[19]  H. Sasano,et al.  Aromatase in aging women. , 1999, Seminars in reproductive endocrinology.

[20]  N. Harada.  Aromatase and Intracrinology of Estrogen in Hormone-Dependent Tumors , 1999, Oncology.

[21]  C. Yang,et al.  Breast tumor aromatase: functional role and transcriptional regulation. , 1999, Endocrine-related cancer.

[22]  G M Clark,et al.  Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  N. Harada,et al.  Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. , 1999, Cancer research.

[24]  N. Harada.  Aberrant expression of aromatase in breast cancer tissues , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  Rod J. Rohrich,et al.  Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. , 1996, The Journal of clinical endocrinology and metabolism.

[26]  N. Harada,et al.  Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. , 1996, The Journal of clinical endocrinology and metabolism.

[27]  A Howell,et al.  Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  N. Harada,et al.  Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. , 1996, The Journal of clinical endocrinology and metabolism.

[29]  N. Harada,et al.  Stromal spindle cells contain aromatase in human breast tumors. , 1994, The Journal of clinical endocrinology and metabolism.

[30]  S. Bulun,et al.  Competitive reverse transcription-polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age. , 1994, The Journal of clinical endocrinology and metabolism.

[31]  N. Harada,et al.  Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Dowsett,et al.  Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. , 1993, Cancer research.

[33]  C. Mendelson,et al.  Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues. , 1991, Molecular endocrinology.

[34]  C. Mendelson,et al.  Tissue-specific expression of human P-450AROM. The promoter responsible for expression in adipose tissue is different from that utilized in placenta. , 1991, The Journal of biological chemistry.

[35]  G. Berkovitz,et al.  Aromatase activity in microsomal preparations of human genital skin fibroblasts: influence of glucocorticoids. , 1989, Journal of steroid biochemistry.

[36]  S. Shousha,et al.  Oestrogen receptors in mucinous carcinoma of the breast: an immunohistological study using paraffin wax sections. , 1989, Journal of clinical pathology.

[37]  C. Mendelson,et al.  Effects of aging and obesity on aromatase activity of human adipose cells. , 1985, The Journal of clinical endocrinology and metabolism.

[38]  R. Santen,et al.  In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. , 1984, The Journal of clinical endocrinology and metabolism.

[39]  M. L. Stone,et al.  Estrogen sulfatase and estrogen sulfotransferase in human primary mammary carcinoma. , 1983, Journal of steroid biochemistry.

[40]  A. Forrest,et al.  Significance of aromatase activity in human breast cancer. , 1982, Cancer research.

[41]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[42]  P. Siiteri,et al.  Plasma Precursors of Estrogen , 1976 .

[43]  P. Siiteri,et al.  Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. , 1974, The Journal of clinical endocrinology and metabolism.

[44]  A. Schindler,et al.  CONVERSION OF ANDROSTENEDIONE TO ESTRONE BY HUMAN FAT TISSUE , 1972 .

[45]  A. Schindler,et al.  Conversion of androstenedione to estrone by human tissue. , 1972, The Journal of clinical endocrinology and metabolism.

[46]  F. Naftolin,et al.  Aromatization of androstenedione by the anterior hypothalamus of adult male and female rats. , 1972, Endocrinology.

[47]  G. Beatson.  On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.